Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

Stefan Faderl, Deborah A. Thomas, Susan O'Brien, Guillermo Garcia-Manero, Hagop M. Kantarjian, Francis J. Giles, Charles Koller, Alessandra Ferrajoli, Srdan Verstovsek, Barbara Pro, Michael Andreeff, Miloslav Beran, Jorge Cortes, William Wierda, Ngoc Tran, Michael J. Keating

Research output: Contribution to journalArticle

Abstract

We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11 + months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.

Original languageEnglish (US)
Pages (from-to)3413-3415
Number of pages3
JournalBlood
Volume101
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Refractory materials
Prolymphocytic Leukemia
Toxicity
B-Cell Chronic Lymphocytic Leukemia
Assays
Neoplasms
Safety
Mantle-Cell Lymphoma
Cytomegalovirus
Leukemia
alemtuzumab
Rituximab
Survival
Infection
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Faderl, S., Thomas, D. A., O'Brien, S., Garcia-Manero, G., Kantarjian, H. M., Giles, F. J., ... Keating, M. J. (2003). Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood, 101(9), 3413-3415. https://doi.org/10.1182/blood-2002-07-1952

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. / Faderl, Stefan; Thomas, Deborah A.; O'Brien, Susan; Garcia-Manero, Guillermo; Kantarjian, Hagop M.; Giles, Francis J.; Koller, Charles; Ferrajoli, Alessandra; Verstovsek, Srdan; Pro, Barbara; Andreeff, Michael; Beran, Miloslav; Cortes, Jorge; Wierda, William; Tran, Ngoc; Keating, Michael J.

In: Blood, Vol. 101, No. 9, 01.05.2003, p. 3413-3415.

Research output: Contribution to journalArticle

Faderl, S, Thomas, DA, O'Brien, S, Garcia-Manero, G, Kantarjian, HM, Giles, FJ, Koller, C, Ferrajoli, A, Verstovsek, S, Pro, B, Andreeff, M, Beran, M, Cortes, J, Wierda, W, Tran, N & Keating, MJ 2003, 'Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies', Blood, vol. 101, no. 9, pp. 3413-3415. https://doi.org/10.1182/blood-2002-07-1952
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 1;101(9):3413-3415. https://doi.org/10.1182/blood-2002-07-1952
Faderl, Stefan ; Thomas, Deborah A. ; O'Brien, Susan ; Garcia-Manero, Guillermo ; Kantarjian, Hagop M. ; Giles, Francis J. ; Koller, Charles ; Ferrajoli, Alessandra ; Verstovsek, Srdan ; Pro, Barbara ; Andreeff, Michael ; Beran, Miloslav ; Cortes, Jorge ; Wierda, William ; Tran, Ngoc ; Keating, Michael J. / Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. In: Blood. 2003 ; Vol. 101, No. 9. pp. 3413-3415.
@article{70e42a6a3dae4685a41d56c8923204c8,
title = "Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies",
abstract = "We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52{\%} (complete remission, 8{\%}; nodular partial response, 4{\%}; partial response, 40{\%}). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11 + months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52{\%} of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27{\%} of the patients, but only 15{\%} were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.",
author = "Stefan Faderl and Thomas, {Deborah A.} and Susan O'Brien and Guillermo Garcia-Manero and Kantarjian, {Hagop M.} and Giles, {Francis J.} and Charles Koller and Alessandra Ferrajoli and Srdan Verstovsek and Barbara Pro and Michael Andreeff and Miloslav Beran and Jorge Cortes and William Wierda and Ngoc Tran and Keating, {Michael J.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1182/blood-2002-07-1952",
language = "English (US)",
volume = "101",
pages = "3413--3415",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

AU - Faderl, Stefan

AU - Thomas, Deborah A.

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Kantarjian, Hagop M.

AU - Giles, Francis J.

AU - Koller, Charles

AU - Ferrajoli, Alessandra

AU - Verstovsek, Srdan

AU - Pro, Barbara

AU - Andreeff, Michael

AU - Beran, Miloslav

AU - Cortes, Jorge

AU - Wierda, William

AU - Tran, Ngoc

AU - Keating, Michael J.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11 + months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.

AB - We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11 + months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.

UR - http://www.scopus.com/inward/record.url?scp=0038724252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038724252&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-07-1952

DO - 10.1182/blood-2002-07-1952

M3 - Article

C2 - 12522009

AN - SCOPUS:0038724252

VL - 101

SP - 3413

EP - 3415

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -